To further characterize the phenotype and potentially detect a further restricted ovarian CSC identity downstream of the SP denominator [19], we extended the panel to include markers implicated in ovarian cancer progression (e.g., CD140a, CD171) [20, 21], epithelial-to-mesenchymal transition (EMT; e.g., CD325) [22], cell migration/chemotaxis (e.g., chemokine receptors) [23], and interaction with the immune system (e.g., HLA-ABC, CD95) [24, 25] (for complete list see Suppl. This evidence concerns the gene PDGFRA and ovarian carcinoma.